Chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Who really needs it.

ABSTRACT:

Objectives

The CSCO and ASCO guidelines in 2021 recommend chemotherapy for stage III-IVA (8th edition of AJCC staging) nasopharyngeal carcinoma (NPC). Actually, patients with stage T3-4N0M0 are often excluded from various clinical trials of the locoregionally advanced NPC, and the survival benefit of chemotherapy in such patients has always been controversial. This study aims to explore the benefit of chemotherapy in patients with locoregionally advanced NPC, especially those with negative lymph nodes.

Methods

A total of 2741 patients were extracted from the SEER database. After a 1:1 PSM analysis, 272 patients were obtained to further explore whether the addition of chemotherapy would achieve survival benefits.

Results

After PSM, Kaplan-Meier curves showed that the o

SUBMITTER: Qu W 

PROVIDER: S-EPMC10067101 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature